Compounds That Target Drug-Resistant Cancer Cells

Challenge
Most known cancer treatment methods (such as chemotherapy and biological-targeted therapies) target cellular pathways that lead to cell death. However, multiple mechanisms such as mutations permit cancer cells to evade these therapies. Cancers such as glioma, lung cancer, prostate cancer and uterine sarcoma particularly become quickly drug-resistant; at that point, their treatment is dramatically more complex and less successful. The development of drugs which work against multi-drug resistant cancers is essential.

Solution
Novel compounds that work against multi-drug-resistant cancers and inhibit the growth of tumors.

Benefits and Features
- Provides innovative therapeutics for control of cancer cell proliferation.
- Works against drug-resistant cancers.

Market Potential / Applications
This invention has applications for medical research centers and in the pharmaceutical industry to develop new drugs for drug-resistant cancers.

Developments and Licensing Status
Status: Available
Commercial sponsor sought? Yes

Patent Status
US patent Issued US 10,414,778 B2
PCT/US2017/029815

Inventors
Snežna Rogelj; Liliyan Frolova; Alexander Kornienko; Sean Henry

Keywords: Cancer, metabolic pathways, apoptosis, metastasis, necrosis, proliferative inhibition

Relevant Paper:

To inquire about this technology call (575) 835-5390 or email us at OIC@nmt.edu
https://www.nmt.edu/oic/